IP Verse

Controlled Release Oral Dosage Forms Of Poorly Soluble Drugs And Uses Thereof - EP2651400

The patent EP2651400 was granted to Amgen Europe on Jan 18, 2023. The application was originally filed on Dec 15, 2011 under application number EP11831805A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2651400

AMGEN EUROPE
Application Number
EP11831805A
Filing Date
Dec 15, 2011
Status
Patent Maintained As Amended
Dec 16, 2022
Grant Date
Jan 18, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TEVA PHARMACEUTICALSMay 6, 2020D YOUNGADMISSIBLE

Patent Citations (37) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0941071
DESCRIPTIONUS2003104053
DESCRIPTIONUS2003104062
DESCRIPTIONUS2008234359
DESCRIPTIONUS2010129445
DESCRIPTIONUS2010168475
DESCRIPTIONUS3536809
DESCRIPTIONUS3598123
DESCRIPTIONUS3845770
DESCRIPTIONUS3916899
DESCRIPTIONUS4008719
DESCRIPTIONUS4915952
DESCRIPTIONUS5059595
DESCRIPTIONUS5073543
DESCRIPTIONUS5120548
DESCRIPTIONUS5354556
DESCRIPTIONUS5451409
DESCRIPTIONUS5591767
DESCRIPTIONUS5639476
DESCRIPTIONUS5674533
DESCRIPTIONUS5733566
DESCRIPTIONUS5945125
DESCRIPTIONUS6210710
DESCRIPTIONUS6217903
DESCRIPTIONUS6635280
DESCRIPTIONUS6723340
DESCRIPTIONUS6962940
DESCRIPTIONWO9722335
EXAMINATIONWO2009120167
INTERNATIONAL-SEARCH-REPORTUS2004254214
INTERNATIONAL-SEARCH-REPORTUS4814176
INTERNATIONAL-SEARCH-REPORTUS6251430
OPPOSITIONWO2004037207
OPPOSITIONWO2006065814
OPPOSITIONWO2007079182
OPPOSITIONWO2009120617
OPPOSITIONWO2010093588

Non-Patent Literature (NPL) Citations (18) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- Burger's Medicinal Chemistry and Drug Discovery, (1995), vol. 172-178, pages 949 - 982-
DESCRIPTION- Current Medical Diagnosis & Treatment, APPLETON & LANGE, (1998), page 499-
DESCRIPTION- EURJ PHARM SCI., (2003), vol. 19, no. 5, pages 345 - 353-
DESCRIPTION- JENS T. CARSTENSEN, Drug Stability: Principles & Practice, MARCEL DEKKER, (1995), pages 379 - 380-
DESCRIPTION- LIST ET AL., J. CLIN. ONCOL., (1990), vol. 8, page 1424-
DESCRIPTION- MAN ET AL., J. MED. CHEM., (2009), vol. 52, pages 1522 - 1524-
DESCRIPTION- The Merck Manual, (1999), page 953-
DESCRIPTION- The United States Pharmacopeia, (1995), pages 1843 - 1844-
OPPOSITION- de la Torre, P.M. et al, "Interpolymer complexes of poly(acrylic acid) and chitosan: influence of the ionic hydrogel-forming medium", Biomaterials, (20030401), vol. 24, no. 8, pages 1459 - 1468-
OPPOSITION- Gul Majid Khan, "Controlled Release Oral Dosage Forms: Some Recent Advances in Matrix Type Drug Delivery Systems", The Sciences, (20011001), vol. 1, no. 5, pages 350 - 354-
OPPOSITION- Gul Majid Khan, "Controlled Release Oral Dosage Forms: Some Recent Advances in Matrix Type Drug Delivery Systems", The Sciences, (20011001), vol. 1, no. 5, pages 350 - 354, XP055761822-
OPPOSITION- Jagdish Balasubramaniam, Bee, Tim, "The influence of superdisinteqrant choice on the rate of drug dissolution", PharmTech, (20090901), vol. 21, no. 9, pages 1 - 2, XP055761833-
OPPOSITION- LATCHMAN, LEIBERMAN et al., "Chapter 14: Sustained Release Dosage Forms", The Theory and Practice of Industrial Pharmacy, pages 430 - 459-
OPPOSITION- Moustafine, R.I. et al, "Characteristics of interpolyelectrolyte complexes of Eudragit E100 with Eudragit L100", Journal of Controlled Release, (20050302), vol. 103, no. 1, pages 191 - 198-
OPPOSITION- Zhilei Lu, Et Al, "Matrix Polymeric Excipients: Comparing a Novel Interpolyelectrolyte Complex with Hydroxypropylmethylcellulose", Drug Delivery, (20080101), vol. 15, no. 2, pages 87 - 96-
OPPOSITION- Zhilei Lu, Et Al, "Matrix Polymeric Excipients: Comparing a Novel Interpolyelectrolyte Complex with Hydroxypropylmethylcellulose", Drug Delivery, (20080101), vol. 15, no. 2, pages 87 - 96, XP055761828-
OPPOSITION- Moustafine, R.I. Kabanova, T.V. Kemenova, V.A. Van den Mooter, G., "Characteristics of interpolyelectrolyte complexes of Eudragit E100 with Eudragit L100", Journal of Controlled Release, AMSTERDAM, NL, (20050302), vol. 103, no. 1, doi:10.1016/j.jconrel.2004.11.031, ISSN 0168-3659, pages 191 - 198, XP004745767
OPPOSITION- de la Torre, P.M. Torrado, S. Torrado, S., "Interpolymer complexes of poly(acrylic acid) and chitosan: influence of the ionic hydrogel-forming medium", Biomaterials, AMSTERDAM, NL, (20030401), vol. 24, no. 8, doi:10.1016/S0142-9612(02)00541-0, ISSN 0142-9612, pages 1459 - 1468, XP004401479

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents